All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know ALL.
The ALL Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your ALL Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe ALL Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the ALL Hub cannot guarantee the accuracy of translated content. The ALL Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The ALL Hub is an independent medical education platform, sponsored by Jazz Pharmaceuticals, Amgen, and Pfizer. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Blinatumomab in adult patients with MRD negative B-ALL: Interim results from the ECOG-ACRIN E1910 trial
Bookmark this article
|
Results from the third interim efficacy analysis of the phase III ECOG-ACRIN E1910 trial (NCT02003222) evaluating blinatumomab in combination with standard consolidation chemotherapy in adult patients with BCR::ABL1 negative B-cell precursor acute lymphoblastic leukemia (B-ALL) in measurable residual disease (MRD) negative remission were published in The New England Journal of Medicine by Litzow et al.1
|
| Key learnings |
|
A total of 224 patients with BCR::ABL1-negative B-ALL in MRD negative remission were included in the analysis.
|
|
At a median follow-up of 43 months, the 3-year overall survival was significantly improved in the blinatumomab group vs chemotherapy alone group (85% vs 68%; hazard ratio for death, 0.41; 95% confidence interval [CI]: 0.23–0.73; p = 0.002). |
|
The 3-year relapse-free survival improved in the blinatumomab group vs chemotherapy alone group (80% vs 64%; hazard ratio for relapse or death, 0.53; 95% CI: 0.32–0.87). |
|
The incidence of treatment-related Grade ≥3 neurologic or psychiatric adverse events was higher in the blinatumomab group vs chemotherapy alone group (23% vs 5%; p < 0.001). |
|
The results suggest an overall survival benefit of the addition of blinatumomab to consolidation chemotherapy in adult patients with BCR::ABL1-negative B-ALL in MRD-negative remission; a longer international follow-up is needed to further confirm. |
- Litzow MR, Sun Z, Mattison RJ, et al. Blinatumomab for MRD-negative acute lymphoblastic leukemia in adults. N Engl J Med. 2024;391(4):320-333. DOI: 10.1056/NEJMoa2312948
Your opinion matters
2 votes - 78 days left ...
Related articles
Newsletter
Subscribe to get the best content related to ALL delivered to your inbox